OPR - Delayed Quote • USD INZY May 2024 5.000 put (INZY240517P00005000) Follow 0.9000 0.0000 (0.00%) At close: April 25 at 10:01 AM EDT Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for INZY240517P00005000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: INZY Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024 Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference Institutional investors own a significant stake of 45% in Inozyme Pharma, Inc. (NASDAQ:INZY) Inozyme Pharma to Participate in Upcoming Investor Conferences Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023 10 Stocks With Huge Catalysts on the Way Inozyme Pharma, Inc. (INZY) Moves to Buy: Rationale Behind the Upgrade
